Study #2023-0900
A Phase I trial of combination Gemcitabine and Nab-Sirolimus in advanced Leiomyosarcomas or advanced Soft-Tissue Sarcomas with TSC2 or TSC1 loss-of-function mutations or deletions
MD Anderson Study Status
Enrolling
Treatment Agent
Gemcitabine, Nab-Sirolimus
Description
To find a recommended dose of gemcitabine and nab-sirolimus that can be given in combination to participants with advanced leiomyosarcomas or soft-tissue sarcomas.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Leiomyosarcoma, Soft-tissue Sarcomas
Study phase:
Phase I
Physician name:
Elise Nassif
Department:
Sarcoma Medical Oncology
For general questions about clinical trials:
1-855-493-3260
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.